메뉴 건너뛰기
The Lancet
Volumn 383, Issue 9915, 2014, Pages 410-
Management of acute myocardial infarction (2)
Author keywords

[No Author keywords available]
Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR;
EID: 84893420454     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60148-3     Document Type: Letter
Times cited : (3)
References (5)
  • 1
    • 84887618830 scopus 로고    scopus 로고
    • Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Final 12 month results of a randomised open-label trial
    • on behalf of the Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investigators
    • Thiele H, Zeymer U, Neumann F-J et al., on behalf of the Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investigators. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: final 12 month results of a randomised open-label trial. Lancet 2013; 382: 1638-45.
    • (2013) Lancet , vol.382 , pp. 1638-1645
    • Thiele, H.1    Zeymer, U.2    Neumann, F.-J.3
  • 2
    • 0345060917 scopus 로고    scopus 로고
    • Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: Data from the CAPTIM randomized clinical trial
    • Steg PG, Bonnefoy E, Chabaud S., et al Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-56.
    • (2003) Circulation , vol.108 , pp. 2851-2856
    • Steg, P.G.1    Bonnefoy, E.2    Chabaud, S.3
  • 3
    • 22544476866 scopus 로고    scopus 로고
    • Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial
    • Theroux P, Armstrong PW, Mahaffey KW, et al Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005; 26: 1964-70.
    • (2005) Eur Heart J , vol.26 , pp. 1964-1970
    • Theroux, P.1    Armstrong, P.W.2    Mahaffey, K.W.3
  • 4
    • 78650165464 scopus 로고    scopus 로고
    • Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction
    • Saia F, Grigioni F, Mazzocchi A., Branzi A. Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction. Am Heart J 2010; 160: S16-21.
    • (2010) Am Heart J , vol.160
    • Saia, F.1    Grigioni, F.2    Mazzocchi, A.3    Branzi, A.4
  • 5
    • 0015226355 scopus 로고
    • Myocardial changes associated with cardiogenic shock
    • Page DL, Caulfield JB, Kastor J.A., et al Myocardial changes associated with cardiogenic shock. N Engl J Med 1971; 285: 133-37.
    • (1971) N Engl J Med , vol.285 , pp. 133-137
    • Page, D.L.1    Caulfield, J.B.2    Kastor, J.A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.